Skip to the main content

Original scientific paper

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study

Božica Matković ; University Hospital for Tumors Zagreb, Croatia
Antonio Juretić ; University of Zagreb, School of Medicine Zagreb, and Zagreb University Hospital Center, Zagreb, Croatia
Giulio C Spagnoli ; Institute of Research and Hospital Management, University of Basel, Basel, Switzerland
Viktor Šeparović ; University Hospital for Tumors Zagreb, Croatia
Marija Gamulin ; Zagreb University Hospital Center Zagreb, Croatia
Robert Šeparović ; University Hospital for Tumors Zagreb, Croatia
Nera Šarić ; Zagreb University Hospital Center Zagreb, Croatia
Martina Bašić-Koretić ; Zagreb University Hospital Center Zagreb, Croatia
Irena Novosel ; Dr. I. Pedišić General Hospital Sisak, Croatia
Božo Krušlin ; University of Zagreb, School of Medicine Zagreb and Sisters of Mercy University Hospital, Zagreb, Croatia


Full text: english pdf 917 Kb

page 171-177

downloads: 589

cite


Abstract

Aim To immunohistochemically evaluate the expression
of MAGE-A1, MAGE-A, and NY-ESO-1 cancer/testis (C/T)
tumor antigens in medullary breast cancer (MBC) tumor
samples and to analyze it in relation to the clinicopathological features.
Methods This retrospective study included samples from
49 patients: 40 with typical MBC and 9 with atypical MBC.
Tumor specimens were obtained from patients operated
on in the University Hospital for Tumors and the Sisters of
Mercy University Hospital, Zagreb, Croatia, from 1999 to
2005. Standard immunohistochemistry was used on archival paraffin-embedded MBC tissues.
Results MAGE-A1, MAGE-A, and NY-ESO-1 antigens were
expressed in 33% (16/49), 33% (16/49), and 22% (11/49) of
patients, respectively. No difference between the groups
with and without C/T tumor antigen expression in age at
diagnosis, tumor size, axillary lymph node metastasis, adjuvant therapy, and HER-2 expression was identified. Significantly more patients died in the MAGE-A-positive group
than in the MAGE-A-negative group (P = 0.010), whereas
a borderline significance was found between MAGE-A1-
positive and the MAGE-A1-negative group (P = 0.079) and
between NY-ESO-1-positive and NY-ESO-1-negative group
(P = 0.117). Overall survival, as evaluated by the KaplanMeier curves, was lower in MAGE-A1- (P = 0.031), MAGE-A-
(P = 0.004), NY-ESO-1-positive groups (P = 0.077).
Conclusion Expression of C/T antigens may represent a
marker of potential prognostic relevance in MBC.

Keywords

Hrčak ID:

71429

URI

https://hrcak.srce.hr/71429

Publication date:

15.4.2011.

Visits: 1.502 *